Golcadomide + Standard Chemotherapy for Brain Lymphoma

This trial tests a new drug, Golcadomide, combined with standard chemotherapy to treat large B-cell lymphoma affecting the brain and spinal cord. Researchers aim to determine if this combination is safe and effective for individuals whose lymphoma has returned or is unresponsive to current treatments. The trial is open to those diagnosed with central nervous system lymphoma, who have tried at least one prior therapy, and are experiencing symptoms like brain or spine issues detected on an MRI. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new drug.

The trial requires that you stop taking certain medications, such as warfarin and strong CYP3A4/5 modulators, before starting the study drug. There is a washout period (time without taking these medications) of 7 days or 5 half-lives, whichever is longer, for strong CYP3A4/5 modulators.

Research has shown that Golcadomide has a promising safety record in early studies. This drug targets specific proteins in cancer cells, aiding the immune system in fighting the cancer. Studies have found it to be generally well-tolerated by patients, indicating that while some side effects may occur, they usually aren't severe enough to halt treatment.

Golcadomide is unique because it combines with standard chemotherapy agents like Pemetrexed, Rituximab, and Dexamethasone to tackle brain lymphoma more effectively. Unlike traditional treatments that primarily focus on one mechanism, Golcadomide may offer a novel method of action by potentially enhancing the effectiveness of these drugs. Researchers are excited because this combination has the potential to improve treatment outcomes and reduce the toxicities usually associated with high doses of chemotherapy.

Research has shown that Golcadomide offers promising results for treating large B-cell lymphoma in the brain. In earlier studies, when combined with standard chemotherapy, Golcadomide led to a reduction in cancer size for 75% of patients. Additionally, 39% of patients achieved complete remission, with no signs of cancer detected. This trial will evaluate Golcadomide in combination with Pemetrexed, Rituximab, and Dexamethasone. Golcadomide targets specific proteins in cancer cells and boosts the immune system to combat the cancer. Its ability to penetrate the brain is particularly beneficial for treating brain lymphomas. These early findings suggest that Golcadomide could be a viable option for those whose cancer has returned or has not responded to other treatments.¹³⁵⁶⁷